An emerging leader in the immunotherapy space, we are advancing a pre-clinical pipeline of therapeutic candidates intended to elicit broad and durable anti-tumor and anti-viral responses and cure disease.
SEC Filings
U.S. Securities and Exchange Commission filings
View SEC Filings
Investor Contact
Will O’Conner
Stern Investor Relations
will.oconnor@sternir.com
Indaptus Management
Indaptus Board of Directors
Corporate Governance
Press Releases
September 15, 2021
Indaptus Therapeutics Receives Notice of Allowance for Strategic Patent
August 3, 2021
Events and Presentations
March 14 – 15, 2022
34th Annual ROTH Conference | Webcast Link
January 10, 2022 at 7AM ET
H.C. Wainwright BioConnect 2022 Virtual Conference | Webcast Link
Documents
November 15, 2021
© 2024. Indaptus Therapeutics. All Rights Reserved. |